The US Food and Drug Administration plans to complete review of Merck & Co. Inc.'s Ebola vaccine application before its March 14 user fee date.
Merck began a rolling submission of the biologics license application for the vaccine, V920 (rVSV∆G-ZEBOV-GP), in October 2018. The FDA...







